• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Phase I Trial of Adenovirus-Mediated IL-12 Gene Transduction in Patients with Recurrent Locally Advanced Prostate Cancer Following Therapy
【24h】

Phase I Trial of Adenovirus-Mediated IL-12 Gene Transduction in Patients with Recurrent Locally Advanced Prostate Cancer Following Therapy

机译：腺病毒介导的IL-12基因转导治疗复发性局部晚期前列腺癌患者的I期临床试验

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with radiorecurrent prostate cancer have few options. Gene therapy may define a treatment option of both local and systemic value. Pre- clinical studies using adenovirus-mediated (Ad.) transduction of IL-12 (Ad.mIL- 12) in a metastatic model of prostate cancer resulted in local growth suppression, survival enhancement and inhibition of pre-established metastases. The basis for these activities include the induction of both innate (neutrophils & NKs) and acquired immunity (T cells). On the basis of these results, we propose to explore the use of Ad.hIL-12 in patients with clinically localized radiorecurrent prostate cancer in a Phase I trial to explore the safety, induction of immune responses and efficacy following therapy. Specific Aims/Study Design: In Aim I patients will be placed in escalating dose cohorts with the primary endpoint of the maximum tolerated dose as determined by physical examination, laboratory values of bodily functions and evidence of IL- 12 gene transduction by measurement of serum by ELISA.. In Aim 2 additional safety data will be recorded through measurement of serum levels of the pro- inflammatory cytokines, TNF- , IFN- and IL-16 by ELISA. In Aim 3 peripheral blood mononuclear cells (PBMCs) will be screened for the induction of T cells, which target the prostate antigens, PSA and PAP via an ELISPOT assay.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号